Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

What Was Tested

In this phase 2 trial, researchers set out to test Survodutide.

It had two arms (groups): Survodutide (experimental) and Placebo (placebo comparator).

Matching Placebo.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 120 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥ 18 years. BMI \>21 kg/m2. Willing to sign an informed consent.

The full record lists 8 inclusion and 29 exclusion criteria; among the exclusions: diagnosis of type 1 diabetes; cardiovascular event within 3 months prior to enrolment; treatment with glp-1ra for \<12 weeks prior to screening.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Survodutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Survodutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2026-03-02 with completion listed for 2027-11-30.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change in first morning void UACR (time frame: From baseline to week 32/36).

It also tracked 8 secondary outcomes, for example eGFR (creatinine, cystatin C, and creatinine-cystatin C), Iohexol measured GFR, UACR and eGFR during 4-week wash-out, Perirenal and renal sinus fat measured by MRI, Subcutaneous and visceral fat assessed by MRI and Body weight.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Survodutide in 120 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Survodutide compound page, all human trials.